Biomarkers, including CD19+ B cells or CD27+ B cells in the peripheral blood, have been used to guide rituximab redosing in different autoimmune diseases such as rheumatoid arthritis [63], with varying success. The gene discussed is CD27; the disease is rheumatoid arthritis.